Experimental Compounds Show Promise Against Aggressive Pancreatic Cancer

A recent study has opened new possibilities for treating one of the deadliest forms of pancreatic cancer, after researchers succeeded in halting the growth and spread of cancer cells using experimental compounds aimed at a gene associated with disease progression.

Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and is classified among the most difficult cancers to treat due to its rapid spread and resistance to existing therapies.

Most cases of this cancer are linked to mutations in the KRAS gene, which plays a key role in regulating cell growth. When mutated, this gene causes cells to divide uncontrollably, leading to tumor formation. For decades, scientists have considered targeting this gene with drugs extremely challenging, often describing it as "undruggable."

To overcome this challenge, a team from the College of Pharmacy and Pharmaceutical Sciences at Florida A&M University tested experimental compounds known as polyisoprenylated cysteinyl amide inhibitors (PCAIs). Unlike previous attempts that targeted specific KRAS mutations, this approach disrupts protein interactions relied upon by various mutations to continue driving cancer growth.

In laboratory experiments on pancreatic cancer cells, these compounds demonstrated a clear ability to slow cancer cell growth and reduce their spread.

The compound NSL-YHJ-2-27 showed the highest effectiveness among those tested, reducing cancer cell migration by more than 90% even at low concentrations.

How These Compounds Affect Cancer Cells

Analyses revealed that these compounds operate through multiple mechanisms simultaneously: they enhance the activity of genes that suppress tumor growth, decrease activity of genes linked to cancer spread, and lower levels of proteins that assist cancer cells in moving and invading neighboring tissues.

Additionally, the compounds disrupted actin filaments, a crucial part of the cell’s internal structure, which impaired the cancer cells’ ability to move and maintain their normal shape.

The researchers also tested the compounds on three-dimensional models that better mimic tumors in the body, where the compounds again successfully induced cancer cell death and disintegrated miniature tumors.

Unexpected Findings and Future Research Directions

The study also uncovered an unexpected outcome: treatment activated certain cancer-related growth pathways excessively instead of suppressing them. The researchers suggest this activation caused the cells to produce large amounts of reactive oxygen species, leading to self-destruction. However, the exact mechanism behind this effect requires further investigation.

The researchers emphasized that these findings are preliminary, as experiments so far have been limited to cultured cells. This necessitates testing the compounds in animal models first, followed by safety and efficacy evaluations in clinical trials before any potential use in patients.

The significance of these results is heightened by the fact that KRAS mutations are not exclusive to pancreatic cancer but are involved in approximately 30% of solid tumors, including colorectal and lung cancers.

The team noted that the compounds were effective against several different KRAS mutations, including KRAS-G12C, KRAS-G12D, and KRAS-G12V, increasing the likelihood of developing a treatment applicable to a broad range of KRAS-related cancers.

The study’s results were published in the journal Oncotarget.